𝗣𝗲𝗽𝘁𝗶𝗱𝗲 𝗛𝗼𝗿𝗺𝗼𝗻𝗲 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗣𝘂𝗿𝘀𝘂𝗶𝘁 𝗼𝗳 𝗞𝗶𝗱𝗻𝗲𝘆 𝗛𝗲𝗮𝗹𝘁𝗵. Brenson is a Post-doc in peptide therapeutics at Purdue University, where he is developing peptide drugs to protect the kidneys from ischemia/reperfusion injury...
Lately you may have noticed a common face around here — maybe you even took a selfie with him. He’s the Peptide King: our mascot for Nitin Shah, Chem-Impex's CEO, who earned his...
We’re excited to invite you to join us for a special evening celebrating the inaugural cohort of The Next Big Thing in Science, a group of early-career scientists shaping what’s...
We're heading to Boston for the 3rd Peptide-Based Therapeutics Summit, April 28-30. And if you're going, we'd love to set aside time to connect!
Meet Chem-Impex's Next Big Thing in Science inaugural cohort: a group of early-career scientists whose ideas, ambition, and perspectives stood out from the crowd, and who are shaping what’s next...
Join us to: Problem-solve your peptide sourcing needs Learn leadership tips at our president's talk "How to Lead Change When You're Not the Boss" Get the scoop on the latest...
A team of students at Keck Graduate Institute is researching the macrocyclic peptide library market, and they'd love to hear from you.
Applications close for The Next Big Thing In Science at 11:59 PM CT on Monday, March 16th. This 6-week, virtual accelerator program is open to early-career peptide scientists who want...
The Next Big Thing in Science is a 6-week cohort program that supports early-career peptide scientists.
We're already gearing up for DCAT, March 23-26 in New York City Meet Chem-Impex at DCAT Week if you're trying to: Find a US partner for Peptide Synthesis Raw...
We wanted to share a brief update regarding dichloromethane (DCM, CAS# 75-09-2) and what it means for your work. Due to the dangers associated with DCM, including toxicity and handling risks,...
We're spending the week at PepTalk in San Diego, Jan 19-22, meeting with teams navigating the realities of peptide development at scale. We support peptide programs from early discovery through...
As 2025 comes to a close, we’re taking a moment to look back on a year full of growth, collaboration, and shared wins. To do that, we’ve been asking ourselves and our customers one...
